Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1984 1
1986 1
1987 2
1989 1
1990 1
1997 1
2001 1
2003 2
2005 6
2007 2
2008 1
2009 5
2011 2
2012 2
2013 6
2014 5
2015 4
2016 7
2017 5
2018 6
2019 13
2020 7
2021 10
2022 6
2023 13
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Laryngeal Squamous Cell Carcinoma"
Page 1
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Ferris RL, et al. N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8. N Engl J Med. 2016. PMID: 27718784 Free PMC article. Clinical Trial.
BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. ...Physical, role, and social functioning was stable in …
BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after plat …
PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy.
Xu Y, Gao Z, Hu R, Wang Y, Wang Y, Su Z, Zhang X, Yang J, Mei M, Ren Y, Li M, Zhou X. Xu Y, et al. J Immunother Cancer. 2021 Oct;9(10):e002699. doi: 10.1136/jitc-2021-002699. J Immunother Cancer. 2021. PMID: 34697216 Free PMC article.
BACKGROUND: Combination therapy has been explored for advanced head and neck squamous cell carcinoma (HNSCC) owing to the limited efficacy of anti-epidermal growth factor receptor (EGFR) therapy. Increased expression and glycosylation of immune …
BACKGROUND: Combination therapy has been explored for advanced head and neck squamous cell carcinoma (HNS …
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Rivera F, García-Castaño A, Vega N, Vega-Villegas ME, Gutiérrez-Sanz L. Rivera F, et al. Expert Rev Anticancer Ther. 2009 Oct;9(10):1421-8. doi: 10.1586/era.09.113. Expert Rev Anticancer Ther. 2009. PMID: 19828002
Expression of EGF receptor (EGFR) is frequently elevated in squamous cell carcinoma of the head and neck (SCCHN). Cetuximab is an anti-EGFR monoclonal antibody that has been shown to improve overall survival in patients with locally advanced SCC …
Expression of EGF receptor (EGFR) is frequently elevated in squamous cell carcinoma of the head and neck …
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial.
Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Ferrarotto R, et al. Adv Ther. 2021 Aug;38(8):4581-4591. doi: 10.1007/s12325-021-01807-6. Epub 2021 Jul 9. Adv Ther. 2021. PMID: 34241781 Clinical Trial.
INTRODUCTION: Patients with advanced cutaneous squamous cell carcinoma (CSCC) have a poor prognosis. Blocking the PD-1-PD-L1 axis has shown promising activity in this patient population. We assessed the safety and antitumor activity of PD-1 inhibitor p …
INTRODUCTION: Patients with advanced cutaneous squamous cell carcinoma (CSCC) have a poor prognosis. Blocking th …
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
Cristina V, Herrera-Gómez RG, Szturz P, Espeli V, Siano M. Cristina V, et al. Int J Mol Sci. 2019 Oct 30;20(21):5399. doi: 10.3390/ijms20215399. Int J Mol Sci. 2019. PMID: 31671550 Free PMC article. Review.
Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at an advanced stage and has a dismal prognosis. ...In this review, we summarize the most important results regarding immune targeting agents for HNSCC, predictive bi …
Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at an advanced stage and has a dismal …
Afatinib in the treatment of head and neck squamous cell carcinoma.
Ferrarotto R, Gold KA. Ferrarotto R, et al. Expert Opin Investig Drugs. 2014 Jan;23(1):135-43. doi: 10.1517/13543784.2014.858696. Epub 2013 Nov 25. Expert Opin Investig Drugs. 2014. PMID: 24266694 Review.
INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of cancer death in the United States. ...Afatinib has clinical activity as a single agent in a subset of refractory and/or metastatic HNSCC patient …
INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of cancer deat …
NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma.
Arora R, Haynes L, Kumar M, McNeil R, Ashkani J, Nakoneshny SC, Matthews TW, Chandarana S, Hart RD, Jones SJM, Dort JC, Itani D, Chanda A, Bose P. Arora R, et al. Cancer Gene Ther. 2023 May;30(5):752-765. doi: 10.1038/s41417-022-00578-8. Epub 2023 Jan 12. Cancer Gene Ther. 2023. PMID: 36635327 Free PMC article.
There are few prognostic biomarkers and targeted therapeutics currently in use for the clinical management of oral squamous cell carcinoma (OSCC) and patient outcomes remain poor in this disease. ...Finally, due to a lack of evidence for the role of NC …
There are few prognostic biomarkers and targeted therapeutics currently in use for the clinical management of oral squamous …
Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review.
Guidi A, Codecà C, Ferrari D. Guidi A, et al. Med Oncol. 2018 Feb 13;35(3):37. doi: 10.1007/s12032-018-1096-5. Med Oncol. 2018. PMID: 29441454 Review.
Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of about 50% for all stages. ...Nowadays, the EXTREME regimen is the standard of care for the first-line treatment of recurrent/metastatic head and neck carcinoma …
Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of about 50% for all stages. ...Nowadays, …
Window-of-opportunity clinical trials for biomarker discovery in head and neck squamous cell carcinoma.
Marret G, Borcoman E, Le Tourneau C. Marret G, et al. Curr Opin Oncol. 2023 May 1;35(3):158-165. doi: 10.1097/CCO.0000000000000940. Epub 2023 Mar 14. Curr Opin Oncol. 2023. PMID: 36966501 Review.
PURPOSE OF REVIEW: We review the window-of-opportunity clinical trials that have been reported in head and neck squamous cell carcinoma (HNSCC), and discuss their challenges. ...Both cetuximab and nivolumab improve overall survival by less than …
PURPOSE OF REVIEW: We review the window-of-opportunity clinical trials that have been reported in head and neck squamous …
The 5-Ws of immunotherapy in head and neck cancer.
Botticelli A, Mezi S, Pomati G, Cerbelli B, Di Rocco C, Amirhassankhani S, Sirgiovanni G, Occhipinti M, Napoli V, Emiliani A, Mazzuca F, Tomao S, Nuti M, Marchetti P. Botticelli A, et al. Crit Rev Oncol Hematol. 2020 Sep;153:103041. doi: 10.1016/j.critrevonc.2020.103041. Epub 2020 Jun 30. Crit Rev Oncol Hematol. 2020. PMID: 32629362 Review.
The immune checkpoint inhibitors, a class of drugs able to block immune suppressive pathways in order to prime an anticancer immunity, revolutionized standard of care in platinum-refractory recurrent and/or metastatic head and neck carcinoma (R/M HNSCC …
The immune checkpoint inhibitors, a class of drugs able to block immune suppressive pathways in order to prime an anticancer immunity, revol …
104 results